Dawn Dansby
Family · Athens, TXNPI 1902276009
Payments from drug & device makers
Across 136 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$411
- Novo Nordisk$293
- Pfizer$213
- Bayer$191
- Boehringer Ingelheim$155
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$138
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,474100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 19 | $411 |
| Novo Nordisk | 18 | $293 |
| Pfizer | 11 | $213 |
| Bayer | 11 | $191 |
| Boehringer Ingelheim | 9 | $155 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $138 |
| Axsome Therapeutics, Inc. | 6 | $136 |
| Lilly USA, LLC | 7 | $134 |
| Amgen | 7 | $113 |
| Lundbeck LLC | 6 | $106 |
| Avanir Pharmaceuticals, Inc. | 5 | $87 |
| GSK | 3 | $77 |
| Mylan Specialty L.p. | 4 | $54 |
| AbbVie | 2 | $44 |
| Biogen | 3 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Amneal Pharmaceuticals LLC | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $31 |
| Abbott | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $21 |
| Boston Scientific | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Almatica Pharma LLC | 1 | $15 |
| Dexcom, Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
How this compares
$2,474 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 111 | $138,865 |
| JardianceEmpagliflozin | 152 | $126,805 |
| RybelsusSemaglutide | 100 | $123,605 |
| RexultiBrexpiprazole | 68 | $105,261 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $54,109 |
| EliquisApixaban | 60 | $50,266 |
| XifaxanRifaximin | 14 | $45,888 |
| KerendiaFinerenone | 53 | $39,934 |
| JanuviaSitagliptin Phosphate | 46 | $32,944 |
| LinzessLinaclotide | 41 | $27,127 |
| MounjaroTirzepatide | 18 | $20,419 |
| MyrbetriqMirabegron | 34 | $17,100 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $15,443 |
| XareltoRivaroxaban | 19 | $15,012 |
| QuliptaAtogepant | 11 | $12,738 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Levemir | $293 | $269,240237 claims |
| Boehringer IngelheimJardiance | $155 | $126,805152 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $411 | $105,26168 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $77 | $69,552104 claims |
| PfizerEliquis | $213 | $50,26660 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $138 | $45,88814 claims |
| BayerKerendia | $191 | $39,93453 claims |
| AbbVieLinzess, Qulipta | $44 | $39,86552 claims |
| Lilly USA, LLCMounjaro | $134 | $20,41918 claims |
| AstraZenecaFarxiga, Symbicort | $17 | $15,55028 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $33 | $5,101570 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.
Other family in Athens
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.